__NUXT_JSONP__("/drugs/Actinium_Ac_225_Lintuzumab", (function(a,b,c,d){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"2209911-94-2",chebiId:b,chemicalFormula:b,definition:"A radioimmunoconjugate consisting of the humanized monoclonal antibody lintuzumab conjugated to the alpha-emitting radioisotope actinium Ac 225 with potential antineoplastic activity. The monoclonal antibody moiety of actinium Ac 225 lintuzumab specifically binds to the cell surface antigen CD33 antigen, delivering a cytotoxic dose of alpha radiation to cells expressing CD33. CD33 is a cell surface antigen expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on myeloid leukemia cells.",fdaUniiCode:"V860J30J9N",identifier:"C82414",preferredName:c,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C1511"],synonyms:["225Ac-HuM195","Actinium (225Ac) Lintuzumab Satetraxetan",c,"Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195","LINTUZUMAB SATETRAXETAN AC-225","SGN-33 AC-225"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FActinium_Ac_225_Lintuzumab",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("Actinium_Ac_225_Lintuzumab","","Actinium Ac 225 Lintuzumab","2021-10-30T13:46:00.953Z")));